Clinical Trials · NCT00713830
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 859
- Start date
- Jul 2008
- Locations
- 16 sites, 16 countries
- Primary endpoint
- Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24